Trevi Therapeutics to Participate in Upcoming June Conferences

Rhea-AI Summary

Trevi Therapeutics (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing Haduvio™ (oral nalbuphine ER) for chronic cough treatments, announced its participation in three major conferences in June 2025. The company will present at the American Cough Conference (June 6-7) discussing RIVER trial demographics for refractory chronic cough. At the CPDD 87th Annual Scientific Meeting (June 14-18), they will present research on nalbuphine's human abuse potential. Finally, at the BIO International Convention (June 16-19), the company will deliver a corporate presentation. Key executives, including CEO Jennifer Good and other senior management, will represent Trevi at these events.

NEW HAVEN, Conn., May 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in June.

American Cough Conference
June 6 – 7, 2025, Dulles, Virginia
Oral Presentation: June 6, 4:05 p.m. ET
Presentation: Baseline demographics and characteristics from the RIVER trial evaluating nalbuphine extended-release tablets in patients with refractory chronic cough
Trevi Representatives: Jennifer Good, President and CEO, James Cassella, Ph.D., CDO, Danine Summers, VP of Medical Affairs and Abbey Nakano, Pharm.D., AD of Medical Affairs
Register here

CPDD 87^th Annual Scientific Meeting
June 14 – 18, 2025, New Orleans, Louisiana
Poster Presentation: June 18, 2:00 p.m. CT
Poster: Assessment of Human Abuse Potential of Nalbuphine in Non-Dependent Recreational Drug Users
Poster Session: 4
Trevi Representative: Thomas Sciascia, M.D., Co-Founder and CSO
Register here

BIO International Convention
June 16 – 19, 2025, Boston, Massachusetts
Corporate Presentation: June 17, 12:15 p.m. ET
Trevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCO
Register here

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically significant reduction in cough frequency in clinical trials with IPF chronic cough patients and RCC patients. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. 

Chronic cough is a highly prevalent condition in IPF patients, impacting up to 85% of the IPF population. There are ~150,000 U.S. IPF patients and the impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients. 

Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, and upper airway cough syndrome or post-nasal drip) and includes unexplained chronic cough. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly debilitating disease and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them.

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.

For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.

Investor Contact
Jonathan Carlson
Trevi Therapeutics, Inc.
(203) 654 3286
carlsonj@trevitherapeutics.com 

Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-upcoming-june-conferences-302467673.html

SOURCE Trevi Therapeutics, Inc.

FAQ

What conferences will Trevi Therapeutics (TRVI) attend in June 2025?

Trevi Therapeutics will attend three conferences: the American Cough Conference (June 6-7) in Dulles, Virginia; the CPDD 87th Annual Scientific Meeting (June 14-18) in New Orleans; and the BIO International Convention (June 16-19) in Boston.

What will Trevi Therapeutics present at the American Cough Conference 2025?

At the American Cough Conference, Trevi will present baseline demographics and characteristics from the RIVER trial, which evaluates nalbuphine extended-release tablets in patients with refractory chronic cough.

What is Haduvio being developed for by Trevi Therapeutics?

Haduvio (oral nalbuphine ER) is being developed for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC).

Who will represent Trevi Therapeutics at the CPDD Annual Scientific Meeting 2025?

Dr. Thomas Sciascia, Co-Founder and CSO of Trevi Therapeutics, will represent the company at the CPDD Annual Scientific Meeting, presenting research on nalbuphine's human abuse potential.